AstraZeneca’s Imfinzi (durvalumab) + Imjudo (tremelimumab) Receive MHLW’s Approval for Advanced Liver and Non-Small Cell Lung Cancers
- The MHLW has approved Imfinzi & Imjudo for liver, biliary tract & lung cancers. Imfinzi + Imjudo approved for unresectable HCC & NSCLC in combination with CT; Imfinzi for unresectable HCC as monotx. & for BTC
- The approval was based on the results from the P-III trials (HIMALAYA & TOPAZ-1) published in NEJM & the P-III trial (POSEIDON) in the Journal of Clinical Oncology. In (HIMALAYA)/(POSEIDON)/(TOPAZ-1) trials, a reduction in risk of death (22%/23%/24% after 6.5mos. of follow-up), patients were alive in the combination therapy vs CT (31% vs 20% after 3yrs./33% vs 22% @2yrs./23.6% vs 11.5% @2yrs.), respectively
- The safety profiles of the combination therapy & Imfinzi as monotx. were consistent with known profiles of each medicine with no new safety signals in all trials
Ref: AstraZeneca | Image: AstraZeneca
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.